Cannabis stocks are pricing in a rescheduling win — here's what happens if they're wrong

The AdvisorShares Pure US Cannabis ETF (MSOS) is trading at its highest level of 2026, delivering a 103.7% one-year NAV return as of May 31 — more than triple the S&P 500's 29.8% gain over the same stretch. The rally is almost entirely a bet on what happens at DEA headquarters by July 15.

The bet has a real foundation: April's move putting FDA-approved and state-licensed medical marijuana products into Schedule III already erased the 280E tax penalty for those categories, an immediate cash-flow win for operators carrying it. Broader rescheduling to Schedule III would extend relief sector-wide and, operators hope, open the door to easier banking and institutional capital.

The individual names show how much upside is priced on speculation rather than earnings: analysts have Verano and Jushi Holdings carrying well over 150% upside targets, and even top MSOS holdings like Green Thumb Industries are pegged near 70% upside. Trulieve, the ETF's largest position at just over 30%, is uplisting to the NYSE this week — a listing move that only makes sense if management expects the tax and banking picture to keep improving.

None of that is guaranteed. The hearing record closes July 15, but DEA still has to issue an actual ruling after that, and nothing stops it from landing short of what the market has already priced in. For an industry that's spent years trading on rescheduling hope rather than rescheduling reality, this is the closest that hope has come to a hard deadline.